Skip to main content

Table 1 Participant characteristics by phenotype of airflow obstruction

From: Adiposity influences airway wall thickness and the asthma phenotype of HIV-associated obstructive lung disease: a cross-sectional study

 

COPD

(n = 23)

No COPD

(n = 98)

p-value

Asthmaa

(n = 33)

No asthma

(n = 88)

p-value

Age, mean (SD)

50.4 (5.7)

43.9 (10.1)

<0.001

43.0 (9.5)

46.0 (9.8)

0.14

Female, n (%)

6 (26.1)

33 (33.7)

0.48

15 (45.5)

24 (27.3)

0.06

African American, n (%)

13 (56.5)

53 (54.1)

0.83

21 (63.6)

43 (48.9)

0.43

BMI (kg/m2), mean (SD)

27.0 (7.9)

27.8 (6.1)

0.58

30.7 (8.1)

26.5 (5.3)

0.008

Smoke status, n (%)

  

0.18

  

0.13

 Never

1 (4.4)

20 (20.4)

 

2 (6.1)

19 (21.6)

 

 Former

7 (30.4)

24 (24.5)

 

21 (23.9)

10 (30.3)

 

 Current

15 (65.2)

54 (55.1)

 

21 (63.6)

48 (54.6)

 

Pack-years smoked, median (range)

20.0 (0-102)

9.8 (0-45)

<0.001

13.5 (0-102)

10.8 (0-75)

0.33

Intravenous drug use (ever), n (%)

3 (13.0)

3 (3.1)

0.05

1 (3.0)

5 (5.7)

0.99

Cocaine use (ever), n (%)

5 (21.7)

23 (23.5)

0.86

5 (15.2)

23 (26.1)

0.20

Marijuana use (ever), n (%)

9 (39.1)

56 (57.1)

0.12

15 (45.5)

50 (56.8)

0.26

HAART use, n (%)

21 (91.3)

85 (86.7)

0.55

28 (84.9)

78 (88.6)

0.57

CD4 count (cells/μl), mean (SD)

578.6 (270.4)

603.5 (339.6)

0.75

596.7 (299.1)

599.9 (338.6)

0.96

HIV RNA level <50copies/mL, n (%)

16 (69.6)

68 (69.4)

0.99

19 (57.6)

65 (73.9)

0.08

Doctor-diagnosed asthma

8 (34.8)

17 (17.4)

0.99

25 (75.8)

0

na

Bronchodilator response

6 (26.1)

8 (8.2)

0.02

14 (42.4)

0

na

Cough

9 (39.1)

26 (26.5)

0.23

14 (42.4)

21 (23.9)

0.05

Phlegm

9 (39.1)

38 (38.8)

0.98

14 (42.4)

33 (37.5)

0.62

Wheeze

12 (52.2)

31 (31.6)

0.06

19 (57.6)

24 (27.3)

0.002

Dyspnea

10 (43.5)

35 (35.7)

0.49

14 (42.4)

31 (35.2)

0.47

pre-BD FEV1 %pred, mean (SD)

72.6 (19.0)

95.8 (16.7)

<0.001

77.7 (20.6)

96.5 (16.2)

<0.001

pre-BD FEV1/FVC, mean (SD)

0.61 (0.09)

0.78 (0.06)

<0.001

0.69 (0.12)

0.77 (0.08)

<0.001

post-BD FEV1/FVC, mean (SD)

0.62 (0.08)

0.81 (0.06)

<0.001

0.73 (0.12)

0.80 (0.08)

0.003

post-BD FEV1/FVC < LLN, n (%)

23 (100)

0 (0)

na

12 (36.4)

11 (12.5)

0.003

DLco % predicted, mean (SD)

0.57 (0.15)

0.68 (0.13)

<0.001

0.63 (0.13)

0.67 (0.14)

0.13

  1. Abbreviations: SD Standard deviation, BMI Body Mass Index, HAART Highly active antiretroviral therapy, BD Bronchodilator, FEV1 Forced expiratory volume in 1 second, FVC Forced vital capacity, %pred Percent predicted, LLN Lower limit of normal, DLco Diffusion capacity of the lung for carbon monoxide
  2. aAsthma phenotype is defined by a history of doctor-diagnosed asthma or a bronchodilator response during pulmonary function testing (Increase in FEV1 or FVC of greater than 200 ml and 12 %)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us